Seeking Innovative Therapies for the Treatment of Skin Disorders

Almirall is a global biopharmaceutical company focused on skin health based in Barcelona. They collaborate with scientists and healthcare professionals to address patient’s needs and make a difference in their lives. They invest in differentiated and ground breaking medical dermatology products to bring their innovative solutions to patients in need. Almirall is seeking partnering opportunities on new assets in preclinical or clinical development stages that could be useful for the treatment of dermatological diseases.

Approaches of Interest

These proposed new assets should:

- Target immuno-inflammatory pathways with rationale for dermatological indications such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo
- Or be suitable for non-melanoma skin cancer (basal and squamous cell carcinoma, and cutaneous T cell lymphoma), or rare dermatological indications (e.g., epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid)
- Involve any therapeutic modality such as small molecules, biologics, mRNA therapeutics or gene therapy approaches

Out of Scope

- Reformulations or drug delivery systems
- Therapeutic approaches to treat melanoma
- Natural products, aesthetic or cosmetics products

Developmental Stages of Interest

- Almirall are interested in opportunities from preclinical to clinical stages up to Phase II clinical trials
- For preclinical assets, compelling in vitro and in vivo evidence of efficacy will be highly valuable

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g., relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Almirall is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and partnership opportunities.